Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype

Alexander J. Thompson, Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, Jacques Fellay, Dongliang Ge, Jeanette J. McCarthy, David B. Goldstein, John G. McHutchison

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)2243-2244
Number of pages2
JournalHepatology
Volume52
Issue number6
DOIs
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Hepatology

Cite this

Thompson, A. J., Muir, A. J., Sulkowski, M. S., Patel, K., Tillmann, H. L., Clark, P. J., Naggie, S., Fellay, J., Ge, D., McCarthy, J. J., Goldstein, D. B., & McHutchison, J. G. (2010). Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology, 52(6), 2243-2244. https://doi.org/10.1002/hep.23826